Infosys’ Post

Don't miss out on this insightful webinar discussing the positive impact of AI-powered analytics on Omni-Channel Marketing initiatives within a Fortune 500 Pharmaceutical company. Join industry experts Sat Chakraborty and Murali Krishna Mylavarapu in conversation with Anant Joshi as they delve into the adoption of Artificial Intelligence for Business Analytics. Register now to gain valuable insights and explore industry best practices #AI #Analytics #Pharmaceuticals #OmniChannelMarketing #Webinar

#Biosimilars Saga - #Role of IT services providers - continued ....#Part 3 #ITservices providers play a pivotal role in the #biosimilars industry by providing technological solutions that enhance efficiency, compliance, and the overall success of biosimilar development, production, and distribution. Their support is essential for companies to navigate the complex and highly regulated landscape of biosimilars. 13. #Data Analytics: IT service providers leverage advanced analytics and data visualization tools to help biopharmaceutical companies make data-driven decisions, optimize processes, and identify areas for improvement in biosimilar development and production. 14. #Training and #Support: IT services providers often offer training and ongoing support to ensure that the users of their systems and software are proficient and can effectively utilize the technology. 15. #CloudComputing: Many IT services providers facilitate the adoption of cloud computing solutions, allowing companies to securely store and access data, collaborate remotely, and scale their operations as needed. 16. #ITStrategy and #Road-mapping: They work with biopharmaceutical companies to develop long-term IT strategies and roadmaps that align with the organization's goals and regulatory requirements, ensuring IT infrastructure evolves with the changing landscape. 17. #CostControl: IT services providers help control IT-related costs by optimizing technology usage and recommending cost-effective solutions. 18. #DisasterRecovery and #BusinessContinuity: They design and implement disaster recovery plans to safeguard critical data and ensure business continuity in the event of unforeseen disruptions. 19. #Automation and #Robotics: In the manufacturing phase, they assist in integrating automation and robotics technologies to improve production efficiency and reduce human error. 20. #Collaborative Platforms: IT services providers develop collaborative platforms that facilitate communication and coordination among geographically dispersed teams working on biosimilar projects. 21. #Market Intelligence: They often provide tools and services to gather market intelligence and competitive insights, helping companies make informed decisions about their biosimilar product portfolio. 22. #Patient and #HealthcareProvider Engagement: In the post-market phase, they help create digital solutions for engaging patients and healthcare providers, enabling better communication and adherence to biosimilar treatments. 23. #Research Collaboration: IT services providers support partnerships and collaborations between biopharmaceutical companies and academic institutions or research organizations, enabling knowledge sharing and innovation If you think, these are the #only things #IT services providers can do in this space ...then stay #tuned, there is lot #more to come! #Watch for this space ...#saga continues....

If you are in #LifeSciences and #BioTech Sector and solving your #Analytics business initiatives using #AI - this Webinar, you do not want to miss! Join us for this Webinar, where our experts Sat Chakraborty and Murali Krishna Mylavarapu discuss with Anant Joshi - how AI-Power Analytics has positive business impact for Omni-Channel Marketing initiatives of a Fortune 500 #Pharmaceutical company. Register here today!! https://lnkd.in/dcPqB6mY Participants will get valuable insights into adoption of Artificial Intelligence for Business Analytics specific to Omni-Channel Marketing Initiatives. We will explore how a Fortune 500 Pharmaceutical company adopted AI to formulate their Next Best Engagement Strategy, Market Evolution. The panel will deep-dive into industry best practices, their relevance and adoption to the UK/EU market. Agilisium Consulting Agilisium Labs Network Science

The pharmaceutical industry is rapidly integrating generative #AI to enhance: Drug Discovery and Development Clinical Trials and Research Biopharmaceuticals Pharma Supply Chain Recent landmark developments at the FDA and strategic insights from Bain & Company, EY, McKinsey & Company, Deloitte, and Boston Consulting Group (BCG) highlight the transformative potential of AI across the pharma and life sciences ecosystem. Key benefits reported include faster #researchanddevelopment, improved clinical trial efficiency, and optimized market intelligence. Effective scaling of AI involves robust data infrastructure, organizational readiness, and continuous adaptation. Responsible AI can lead to significant productivity gains, accelerate innovation, and improved patient outcomes, positioning the industry for a robust personalized medicine future. Forward thinking pharma leaders of enterprises that wish to gain competitive advantage must revise and recalibrate their #digitalstrategy to incorporate AI in their innovation pipeline. #AI #Pharma #Innovation #Healthcare #Technology #healthtech #precisionhealth #smarthealth Image courtesy of Davinci via RevExpoConsulting's XStudio

Accenture’s “Technology Vision 2023 for Biopharma” reveals AI trends in 2024. From growing drug discovery investments to reinventing the BioPharma value chain, we recap the full report: https://bit.ly/47IgUdc #pharma #innovation #ai #artificialintelligence #biopharma #generativeai #genai #pharmaceutical #lifesciences #healthcare #llm #llms

Interesting short analysis in Nature Reviews Drug Discovery early publishing by Alexander Roland and Ann Baker. My favourite theme: decision making. Or as they reason to understand the large variation in R&D efficiency in the cohort they analysed: „If a given company’s R&D efficiency problem is primarily driven by low late-stage success rates, for example, several root causes might be considered. Have low-quality projects been progressing owing to poor decision-making around success criteria in early-stage research, effectively delaying attrition to later stages? Or could problems be due to portfolio rationalization following a major merger, or perhaps a short-term impact of therapeutic area refocusing? Real-world precedents exist for these scenarios and more.“ Speaking from my own experience, companies are still taking shortcuts and leave out too much important data, which in turn makes data driven decisions difficult (as the data is not there). Question based approaches assure you can carefully consider your assets. Does it translate? What part of the clinical data? Are the (animal) models merely revealing target validity? Can we meassure biological effects? Biomarkers in place? Validated? We seem very molecular driven until we enter the clinical domain…

𝐃𝐚𝐭𝐚-𝐃𝐫𝐢𝐯𝐞𝐧 𝐏𝐡𝐚𝐫𝐦𝐚- 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐌𝐋 Data analytics and machine learning empower the pharmaceutical sector through advanced insights, streamlined processes, and personalized interventions. How it functions is as follows: - 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: Analytics identify potential drug candidates efficiently. 𝐎𝐮𝐭𝐜𝐨𝐦𝐞: Accelerates drug discovery, reducing time and costs. 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: ML enhances patient selection and trial design. 𝐎𝐮𝐭𝐜𝐨𝐦𝐞: Improves trial success rates and speeds up the drug development timeline. 𝐒𝐮𝐩𝐩𝐥𝐲 𝐂𝐡𝐚𝐢𝐧 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: Analytics predict demand and optimize supply chain processes. 𝐎𝐮𝐭𝐜𝐨𝐦𝐞: Enhances efficiency, reduces waste, and ensures timely medication availability. 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: ML analyzes patient data for tailored treatments. 𝐎𝐮𝐭𝐜𝐨𝐦𝐞: Facilitates the development of personalized medicine, improving patient outcomes. 𝐀𝐝𝐯𝐞𝐫𝐬𝐞 𝐄𝐯𝐞𝐧𝐭 𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: ML models identify potential negative effects. 𝐎𝐮𝐭𝐜𝐨𝐦𝐞: Enhances drug safety measures, minimizing risks during and after market release. The pharmaceutical industry is transformed by the combination of data analytics and machine learning, which promotes efficiency, creativity, and a more individualized approach to patient care and medication discovery. #dataanalytics #machinelearning #technology #healthcare #pharmaceutical #industry #solutions #trends #innovation #intelliquity

𝐆𝐞𝐧𝐀𝐈'𝐬 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐑𝐞𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 This insightful interview is featured in "𝐀 𝐒𝐩𝐞𝐜𝐢𝐚𝐥 𝐈𝐬𝐬𝐮𝐞 𝐨𝐧 𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 (𝐀𝐈) 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚," Issue 55 of Pharma Focus Asia Magazine" We are witnessing a monumental shift in the pharmaceutical industry, driven by the groundbreaking potential of 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐀𝐈 (𝐆𝐞𝐧𝐀𝐈). In a recent interview, experts Sameer Lal, John Ward, and Dr. Andrée Bates delved into the transformative power of #GenAI and its implications for #drugdevelopment and commercialization. 𝐊𝐞𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐈𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰: ✅Sameer Lal: Discusses how 𝐆𝐞𝐧𝐀𝐈 is reshaping the #pharma landscape, emphasizing emerging trends and regulatory challenges. Gain valuable insights for navigating the evolving AI-driven industry. ✅John Ward: Highlights the integration of 𝐆𝐞𝐧𝐀𝐈 technologies, enhancing drug discovery, streamlining manufacturing, and optimizing knowledge management. Discover #methodologies for implementing GenAI tools like automated document generation and AI-driven simulation models. ✅Dr. Andrée Bates: Explores the promise of 𝐆𝐞𝐧𝐀𝐈 in automating drug design, accelerating #clinicaltrials, and personalizing sales and marketing. Understand the meticulous planning needed to manage risks and fully realize these advancements. 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐢𝐧 𝐞𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐡𝐨𝐰 𝐆𝐞𝐧𝐀𝐈 𝐢𝐬 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐩𝐡𝐚𝐫𝐦𝐚! 🔗https://lnkd.in/d2b38pmV Click the link below to explore this insightful 𝐄-𝐁𝐨𝐨𝐤 and start shaping the future of your organization today! 🔗𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐄-𝐁𝐨𝐨𝐤: https://lnkd.in/eBQD_FfQ 🔗𝐒𝐭𝐚𝐲 𝐮𝐩𝐝𝐚𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐥𝐚𝐭𝐞𝐬𝐭 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐛𝐲 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐢𝐧𝐠 𝐡𝐞𝐫𝐞: https://lnkd.in/ghDSEXKj 🔗𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐨𝐮𝐫 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞 𝐈𝐬𝐬𝐮𝐞𝐬: https://lnkd.in/gAdrmXdF 🔗𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐚𝐝𝐯𝐞𝐫𝐭𝐢𝐬𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚? 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐨𝐮𝐫 𝐦𝐞𝐝𝐢𝐚 𝐩𝐚𝐜𝐤 𝐡𝐞𝐫𝐞: https://lnkd.in/dbaBPC8E. #PharmaInnovation #GenAI #DrugDevelopment #AIinHealthcare #PharmaIndustry #GenerativeAI #HealthcareTech #AIDriven #ClinicalTrials #PharmaTransformation #RegulatoryAffairs #DigitalTwins #MedicalAffairs #TechInPharma

Have you thought about how scientists take the lead on digital transformation? Daniel Tabas has a perspective to share in his blot post. Check it out!

From escalating drug discovery costs to regulatory demand and supply chain uncertainties, the landscape of pharma companies is both challenging and complex. However, there's a solution: Lab transformation.   Capgemini’s latest #PharmaIndustry research reveals that organisations leading in next-gen lab development gain significant advantages, including faster time to market and improved approval rates. These industry front-runners excel by fostering agile and sustainable lab environments through innovative technology and streamlined processes.   Want to learn how to create your organisation's #LabOfTheFuture? Read our report here: https://lnkd.in/eSGqUvFB   #DigitalLab #FutureLab #TeamBayer